AgomAb Therapeutics IPO 2026

TLDR

AgomAb Therapeutics raised $200M in an IPO on the Nasdaq in February 2026 at $16 per share, implying a valuation of approximately $780M, with JP Morgan and Morgan Stanley as underwriters.

Overview

AgomAb Therapeutics listed on the Nasdaq under the ticker AGMB in February 2026, raising $200M at $16 per share. The listing values the company at approximately $780M, making it one of the most significant Belgian biotech public listings in recent years.

The IPO was underwritten by JP Morgan and Morgan Stanley, two of the most active biotech IPO banks, signaling institutional confidence in AgomAb's fibrosis antibody pipeline.

AgomAb was spun out of argenx, Ghent's globally recognized antibody platform company. The Nasdaq listing follows the path of argenx itself and reflects a broader pattern of Belgian biotech companies accessing US public markets for growth capital.